Illumina (ILMN)
(Delayed Data from NSDQ)
$121.56 USD
+1.13 (0.94%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $121.00 -0.56 (-0.46%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth C Momentum C VGM
Brokerage Reports
0 items in cart
Illumina, Inc. [ILMN]
Reports for Purchase
Showing records 221 - 240 ( 363 total )
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Full 3Q15 Results Somewhat Encouraging - Multiple Paths to 2016 Improvement - FCF Impressive - Maintain OP - Upping PT to $160
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
3Q Preannouncement Driven By Weaker Desktop System Sales in EU - AsiaPac - Key High End Systems - Consumables Remain Solid - Lowering PT to $150
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z